



# **TRANSFUSION REACTIONS**

Dr. Soudabeh Haddadi Associate Professor of Anesthesia GUMS Nov. 2021

1- عوارض حاد تزريق خون: - واكنشهاي خفيف: - واکنشهای کهیری آلرژیک - واکنشهای متوسط: – واکنشهای کهیری شدید – واکنشهای تب زای غیر همولیتیک - تماس احتمالي با عوامل باكتريايي - واكنشهاي تهديد كننده حيات: - هموليز داخل عروقي حاد - شوك سيتيك ناشي از عوامل باكتريايي - افزایش حجم مایع - واکنشهای آنافیلاکتیک – آسيب هاي ريوي وابسته به تزريق ۲- عوارض تاخيري تزريق خون: - عفونت هاى منتقله توسط تزريق خون ( هپاتيت ، ايدز ، شاگاس، مالاريا، سايتومگالوويروس، سيفليس) - ساير عوارض تاخيرى: - واكنش هموليتيك تاخيري – پورپورای بعد از تزریق خون GVHD -– افزایش تجمع آهن

#### **HEMOLYTIC TRANSFUSION REACTION**

- In 2011 the incidence of an acute hemolytic transfusion reaction resulting from ABO incompatibility was 1:1200 to 1:190,000
- Intravascular hemolysis occurs when there is a direct attack on transfused donor cells by recipient Ab and complement
- Such reaction can occur from infusion of as little as 10 ml of blood



### Signs and Symptoms

- The clinical consequences are very serious but quite variable.
  Factors include :
  - 1- volume of transfused blood
  - 2- number of antigenic sites on the cell membrane
  - 3- activity of the reticuloendothelial system
  - 4- properties of the Ab ( concentration & ability to activate complement )
- A sample of plasma that contains 2 mg/dl of Hb is faintly pink or light brown. When reaches to 100 mg/dl the plasma is red and when reaches to 150 mg/dl hemoglobinuria is occurs.

#### Lab tests : serum haptoglobin plasma & urine Hb bilirubin direct antiglobulin ( can confirm the presence of hemolysis )

#### FREQUENCY AND SIGNS AND SYMPTOMS OF HEMOLYTIC TRANSFUSION REACTIONS IN 40 PATIENTS

Sign or Symptom	No. Patients	
Fever	19	
Fever and chills	16	
Chest pain	6	
Hypotension	6	
Nausea	2	
Flushing	2	
Dyspnea	2	
Hemoglobinuria	1	



### direct antiglobulin test

#### Treatment

- Blood & urine samples should be sent to the laboratory
- Blood bank should check all paperwork & lab tests should be performed :
  - direct antiglobulin test
  - repeat compatibility testing
  - repeat other serologic tests
  - U/A for hemoglobinuria
- Renal & coagulation system are affected
- **ARF** : Hb in the form of acid hematin precipitate in the distal tubule and is inversely related to the volume of urine flow & its PH
- Maintain U/O > 75 ml/h by IV fluid & diuretics
- Crystalloid to maintain the CVP between 10-15 cm H2O + 12.5 50 g manitol or diuretics (furosemide)
- Alkalization of the urine
- **DIC**: RBC stroma is severed releasing erythrocytin , which activates the intrinsic system of coagulation
- Lab tests: Plt , PT , PTT ( baseline values for subsequent compare )
- **Hypotension** : result from activation of the kallikrein system ( plasma kininogen is converted to bradykinin , a potent vasodilator)

#### Steps in the Treatment of a Hemolytic Transfusion Reaction

- 1. STOP THE TRANSFUSION.
- 2. Maintain the urine output at a minimum of 75 to 100 mL/hr by the following methods:
  - a. Generously administer fluids intravenously and possibly mannitol 12.5 to 50 g, given over 5 to 15 minutes.
  - b. If intravenously administered fluids and mannitol are ineffective, administer furosemide (20 to 40 mg) intravenously.
- 3. Alkalinize the urine; because bicarbonate is preferentially excreted in the urine, only 40 to 70 mEq of sodium bicarbonate per 70 kg of body weight is usually required to raise the urine pH to 8, whereupon repeat urine pH determinations indicate the need for additional bicarbonate.
- 4. Assay urine and plasma hemoglobin concentrations.
- 5. Determine platelet count, partial thromboplastin time, and serum fibrinogen level.
- 6. Return unused blood to blood bank for repeat crossmatch.
- Send patient's blood and urine sample to blood bank for examination.
- 8. Prevent hypotension to ensure adequate renal blood flow.

#### TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI)

- The common cause of transfusion-related fatalities
- TRALI is a noncardiogenic pulmonary edema
- Clinically appear 1-2 hours after transfusion & are in force within 6 hours
- Fever, dyspnea, fluid in the ETT, severe hypoxia
- All blood components , especially FFP
- Treatment : stopping the transfusion & critical care support
- Most patients recover within 96 hours
- Risk factors: higher IL-8 ,liver surgery, chronic alcohol abuse, shock, higher peak airway pressure during M.V, smoking, positive fluid balance

# TRALI vs. Normal Lung



#### TRANSFUSION-RELATED FATALITIES IN THE UNITED STATES, 2008 THROUGH 2012

Cause of Fatality	2008 to 2012	2012
TRALI	74	17
Other reactions (non-	53	8
ABO hemolytic therapy, anaphylaxis)		
Bacterial contamination	21	3
ABO hemolytic transfusion	22	3
Transfusion not ruled out	99	27

From Fatalities Reported to FDA following blood collection and transfusion: annual summary for fiscal year 2012. These reports are available online. at http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm346639.htm TRALI, Transfusion-related acute lung injury.

#### DELAYED HEMOLYTIC TRANSFUSION REACTION

- The transfused donor cells may survive well initially, but after a variable delay (2-21 days) they are hemolysed.
- Occurs in recipients sensitized to RBC Ag by previous blood transfusions or pregnancy
- In which the level of Ab at the time of transfusion is too low & RBC destruction occurs only when the level of Ab is increased after secondary stimulus
- Often manifested only by a decrease in the post transfusion Hct
- Jaundice & hemoglobinuria can occur and can cause impairment in renal function, but only rarely lead to death
- Are in the Rh & kidd systems rather than the ABO system
- Not be preventable, because pre transfusion testing is unable to detect very low level of Ab



#### NONHEMOLYTIC TRANSFUSION REACTIONS

- Usually are not serious and are febrile or allergic
- Fever may be the first sign of a hemolytic reaction or of bacterial contamination

### 1- Febrile reactions

- Symptoms : chills, fever, headache, myalgia, nausea, nonproductive cough, (less common :) hypotension, chest pain, vomiting, dyspnea, pulmonary infiltration in CXR
- Caused by pyrogenic cytokines & intracellular contents released by donor leukocytes
- Use of leukoreduced blood lowered the incidence of febrile reaction
- **Direct antiglobulin test** can differentiates a hemolytic reaction from a febrile reaction
- No clear consensus exist on whether the transfusion should be determinate

#### Febrile Transfusion Reaction Algorithm

Differential Dx: Acute/delayed hemolytic reaction, bacterial contamination,

FNHTR (febrile non-hemolytic transfusion reaction), TRALI, pre-existing conditions



### 2- Allergic reactions

- Can be minor anaphylactoid or anaphylactic
- An anaphylactoid reaction is clinically similar to anaphylaxis, but it is not mediated by IgE

#### A- anaphylactoid reaction

- Most are minor & caused by the presence of foreign protein in the transfused blood
- Symptoms: urticaria with itching (most common) facial swelling (occasionally)
- Transfusion does not need to be discontinued
- Treatment: antihistamines





### **B- anaphylaxis**

- Symptoms: dyspnea, hypotension, laryngeal edema, chest pain, shock
- caused by the transfusion of IgA to patients who are IgA deficient & have formed anti-IgA
- Occurs very rapidly, after transfusion of only a few ml of blood or plasma
- Patients who experience these anaphylactic reactions can be given transfusion with washed RBC



### **OTHER NONINFECTIOUS RISKS**

 The term NISHOT ( non infectious serious hazards of transfusion ) includes all noninfectious complication

# 1- transfusion-associated circulatory overload (TACO)

- Refers to an excessive administration of blood
- Risk factors :
  - cardiopulmonary dis.
  - renal failure
  - extremes of age (especially infants)
- Decrease the rate of transfusion & diuretics may be helpful

# TRALI vs. TACO



## TRALI

# TACO

#### Signs & Symptoms

- Respiratory distress
- Tachypnea
- Hypoxemia
- Hypotension
- Noncardiogenic pulmonary edema
- Fever
- Onset within 6 hours of transfusion

#### Supporting Data

- B/L pulmonary infiltrates on CXR
- Decreased WBC count
- Associated with HLA and/or Neutrophil Antibodies

#### Signs & Symptoms

- Respiratory distress
- Tachypnea
- Hypoxemia
- Hypertension
- Cardiogenic pulmonary edema
- Improves with diuretics

#### Supporting Data

- B/L pulmonary infiltrates on CXR
- Pretransfusion fluid overload
- Elevated BNP
- Increased heart size
- Vascular congestion
- Pulmonary wedge P > 18 mm Hg



# 2- transfusion-related immunomodulation (TRIM )

 Blood transfusion can suppress the immune system because of circulating lymphocytes

### 3- microchimerism

- Refers to more than one cell line in an individual organism
- Donor lymphocytes may persist in a patient
- It is associated with pregnancy , transplant , and trauma
- Out-come is not known

### 4- post transfusion purpura

- Refers to recipient alloantibodies attacking donor platelet Ag
- Treated with IV immunoglobulin



### 5- hypotensive transfusion reaction

 Activation of the coagulation pathway activates production of bradykinin & allergic reaction

#### 6- transfusion-associated graft-versushost disease (TA-GVHD)

- Refers to transfusion into an immunocompromised host
- Is an extremely serious & fatal problem

# Transfusion Associated Graftvs-Host Disease (TA-GVHD)

- Incidence: Rare
- Etiology: Donor lymphocytes engraft in recipient and mount an attack on the host tissues
- Presentation: Rash, erythroderma, maculopapular rash, anorexia, nausea, vomiting, diarrhea, hepatitis, pancytopenia, fever, bone marrow fibrosis and failure
- Lab testing:
  - Skin biopsy
  - Bone marrow biopsy and HLA typing



### 8- alloimmunization

 Only 2-8% of recipients who are chronically transfused develop RBC alloantibodies

### 9- iron overload

- It is the results of chronic transfusion therapy
- Iron deposits into vital organs
- Fatal liver or heart dysfunction , or both , can occur



# 1 unit of PRCs has ~ 250 mg of Iron Removed by body 1 mg / day

accumulate iron

Hemosiderosis

iron accumulate

Hemochromatosis

	Incidence (per 10 <sup>5</sup>			
Transfusion Reaction	Transfusions)	Etiology	Therapy	Prevention
Febrile	All components: 70-6800	Storage-generated proinflammatory cytokines Patient antileukocyte antibodies bind to donor leukocytes	Stop transfusing Give antipyretics Supportive care	Prestorage leukoreduction
ΤΑϹΟ	All components: 16.8-8000 Practice-dependent	Circulatory overload Patients with cardiac or renal disease, infants, and the critically ill are at increased risk	Stop transfusing Give diuretics Oxygen	ldentify patients at high risk Transfuse slowly
TRALI	Erythrocytes: 10-20 Platelets/plasma: 50-100	Passive transfusion of donor antibodies Storage-generated toxic lipids	Supportive care	Remove high-risk donors from the donor pool
Allergic	All components: 3000 mild, 2 anaphylactic	Mild reactions: Transfusion of soluble antigens in donor plasma Anaphylaxis: IgA deficiency or other recipient protein deficiency	Stop transfusing ASA monitors Large-bore IV access Epinephrine Antihistamines Supportive care	Pretransfusion antihistamine use remains common practice despite limited evidence
Hemolytic	Erythrocytes: 1.1-9.0	Donor antibodies bind to patient erythrocytes Patient antibodies bind to donor erythrocytes	Stop transfusing Repeat matching Supportive care Treat DIC	Standard operating procedures
TRIM	Unknown	The mechanism is unknown but may depend on the presence of donor leukocytes	Treat complications (e.g., infection, malignancy)	Prestorage leukocyte reduction may be beneficial, but this approach is controversial
Microchimerism	All components: 5000- 10,000 massive transfusion	Permanent residence of donor cells in recipient	Unknown	Unknown
Posttransfusion purpura	All components: 2	Recipient alloantibodies attack donor platelet antigens	IVIG	Avoid units positive for implicated HPA antigens in patients with a history of PTP
Hypotensive	Unknown	Production of kinins by the activation of the contact system Patients on ACE inhibitors are at increased risk	Stop transfusing ASA monitors Large-bore IV access Supportive care	Avoid the use of negatively charged leukocyte reduction filters
Graft-versus-host	Varies by patient population	Transfusion into immunocompromised host Transfusion of donor cells closely matching HLA type	No consensus exists Consider bone marrow transplant	Gamma irradiation of cellular products

#### TABLE 61-9 NONINFECTIOUS HAZARDS OF TRANSFUSIO

#### TRANSFUSION-TRANSMITTED INFECTION

 The use of more sensitive screening tests and changes in transfusion medicine practices has made these infectious risks quite rare

#### PERCENTAGE RISK OF TRANSFUSION-TRANSMITTED INFECTION WITH A UNIT OF SCREENED BLOOD IN THE UNITED STATES

Infection	Risk	Window Period (Days)
Human immunodeficiency virus-1 and -2	1:1,476,000	5-6
Human T-lymphotropic virus (HTLV-II)	1:2,993,000	51
Cytomegalovirus (CMV)	Infrequent with leukocyte-reduced components	
Hepatitis C virus (HCV)	1:1,149,000	3-4
Hepatitis B virus (HBV)	1: 280,000	24
Hepatitis A virus (HAV00)	1:1,000,000	
Bacteria red blood cells	1:1,000 with septic reaction in 1:500,000	
Pheresis platelets (with early aerobic culture)		
Parasites: Babesia and malaria	<1:4,000,000	7-14
West Nile virus (WNV)	1/1,100,000	?
Acute hemolytic transfusion reactions	1:38,000-1:70,000	

#### Infectious Disease Testing for Blood Transfusions: 1998

- 1. Discontinue serum alanine aminotransferase testing
- 2. Hepatitis C antibody testing
- 3. Antibody to hepatitis B core antigen
- 4. Human immunodeficiency virus (HIV) type 1
- 5. HIV-2
- 6. HIV Ag (p24 antigen)
- 7. Human T-cell lymphotropic virus (HTLV) types 1 and 2
- 8. Serologic test for syphilis

avoidance of unnecessary transfusions will be the most effective way to reduce complications of blood transfusions !

